Text Correction
There was an error in the original publication [1]. “Percentages presented in the text in the seventh (36.8% vs. 19.0%) and eighth sentences (9.6%; 2.1%) were errors and did not match those in Table 5 of which they were referenced”.
A correction has been made to 3. Results section, 3.3. Impact of Primary Endpoint Occurrence on Clinical Outcomes and Adverse Events subsection, first paragraph, seventh and eighth sentences:
Courses in which DME occurred required significantly longer delays prior to the next course of treatment compared to courses without DME occurrence (Table 5). Hospital LOS for chemotherapy was significantly longer in courses in which DME occurred (5.3 days, IQR 4.2–9.1) compared to those with no DME (4.2 days, IQR 3.7–6.1). Similarly, courses with AKI and DME + AKI required longer hospital LOS compared to courses without AKI and DME + AKI, respectively. The proportion of courses that required rehospitalization for toxicity was smaller in courses with DME (4.0%) compared to those without DME (6.1%); however, the median LOS of rehospitalization for toxicity management was 1.4 days longer in courses with DME. In contrast, courses with AKI occurrence were observed to have a higher incidence (7.8% vs. 5.5%) of rehospitalization but shorter LOS (3.5 days vs. 5.1 days) than those without AKI. However, these differences in rehospitalization were not significant. Methotrexate dose omission in the subsequent course occurred more frequently in courses that experienced DME, AKI, and DME + AKI compared to those that did not: 9.6% vs. 2.1%, 4.9% vs. 2.7%, and 7.5% vs. 2.8%, respectively. Methotrexate dose reduction in the subsequent course was required more frequently in courses with DME (27.8%) than those without DME (17.3%), whereas it was required less frequently in courses with AKI occurrence (12.5%) compared to those without AKI (19.7%).
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Pourroy, B.; Aumente, M.D.; Koenecke, C.; Stanulla, M.; Ferreri, A.J.M.; Murciano-Carillo, T.; Dandapani, M.; Ritzmann, T.A.; Barba, P.; Chatelut, E.; et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.